Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT ) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.
Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI's proprietary approach may overcome these challenges by:
'I'm pleased with Tevogen.AI's continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.'
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
United's Cost Discipline Shines as UBS Boosts Estimates
Thomas Wadewitz at UBS saw United Airlines (NASDAQ:UAL) cautious EPS guide as a green flag for Newark's recovery and rising corporate travel, so he boosted his price target to $114 and tweaked EPS forecasts. He now pegs Q4 EPS at $2.90 and FY 26 at $14.25, reflecting tight cost discipline. United held unit costs excluding fuel to just 2.2% growth even after front?loading flight attendant signing bonuses. Warning! GuruFocus has detected 3 Warning Sign with UAL. That efficiency stemmed from strong network operations as capacity climbs five to six percent. United expects unit costs ex fuel to stay near 2.5% in the second half as demand picks up. All eyes are on next week's results from Delta, American, Southwest and JetBlue. How United balances improving demand with cost control will decide if UBS's bullish outlook holds. This article first appeared on GuruFocus.
Yahoo
18 minutes ago
- Yahoo
Third Fatal Liver Failure Hits Sarepta Gene Trial
Sarepta (NASDAQ:SRPT) has now seen a third fatal incident in its gene therapy trials due to acute liver failure. That happened last month in a limb girdle muscular dystrophy study and follows two teenage deaths in advanced Duchenne muscular dystrophy patients. The trial was halted and Elevidys distribution paused for non walking patients. Warning! GuruFocus has detected 3 Warning Signs with SRPT. The company reported the latest death promptly to regulators and agreed to alert doctors and patients about liver failure risks as the FDA requested. Talks are underway on how to protect non walking patients going forward. To steady its finances, Sarepta will cut more than a third of its workforce and pause several drug programs. This move is expected to save around four hundred million dollars a year. Investors will watch closely for signs that these steps can rebuild confidence. This article first appeared on GuruFocus.
Yahoo
18 minutes ago
- Yahoo
Did money or politics cause Colbert cancellation? Either way, the economics are tough for TV
CBS says its decision to end Stephen Colbert's late-night comedy show is financial, not political. Yet even with the ample skepticism about that explanation, there's no denying the economics were not working in Colbert's favor. The network's bombshell announcement late Thursday that the 'Late Show' will end next May takes away President Donald Trump's most prominent TV critic and the most popular entertainment program in its genre. The television industry's declining economic health means similar hard calls are already being made with personalities and programming, with others to be faced in the future. For the late-night genre, there are unique factors to consider. As recently as 2018, broadcast networks took in an estimated $439 million in advertising revenue for its late-night programs, according to the advertising firm Guidelines. Last year, that number dwindled to $220 million. Once a draw for young men, now they've turned away Late-night TV was a particular draw for young men, considered the hardest-to-get and most valuable demographic for advertisers. Increasingly, these viewers are turning to streaming services, either to watch something else entirely or catch highlights of the late-night shows, which are more difficult for the networks to monetize. More broadly, the much-predicted takeover of viewers by streaming services is coming to pass. The Nielsen company reported that during the last two months, for the first time ever, more people consumed programming on services like YouTube and Netflix than on ABC, CBS and NBC or any cable network. Networks and streamers spent roughly $70 billion on entertainment shows and $30 billion for sports rights last year, said Brian Wieser, CEO of Madison & Wall, an advertising consultant and data services firm. Live sports is the most dependable magnet for viewers and costs for its rights are expected to increase 8% a year over the next decade. With television viewership declining in general, it's clear where savings will have to come from. Wieser said he does not know whether Colbert's show is profitable or not for CBS and parent company Paramount Global, but he knows the direction in which it is headed. 'The economics of television are weak,' he said. In a statement announcing the cancellation, George Cheeks, Paramount Global's president and chief executive officer, said that 'This is purely a financial decision against a challenging backdrop in late night. It is not related in any way to the show's performance, content or other matters happening at Paramount.' Cheeks' problem is that not everyone believes him. Colbert is a relentless critic of Trump, and earlier this week pointedly criticized Paramount's decision to settle Trump's lawsuit against CBS over a '60 Minutes' interview with Kamala Harris. He called Paramount's $16 million payment to Trump a 'big fat bribe,' since the company is seeking the administration's approval of its merger with Skydance Media. On Friday, the Writers Guild of America called for an investigation by New York's attorney general into whether Colbert's cancellation is itself a bribe, 'sacrificing free speech to curry favor with the Trump administration as the company looks for merger approval.' CBS' decision made this a pivotal week for the future of television and radio programming. Congress stripped federal funding for PBS and NPR, threatening the future of shows on those outlets. Journey Gunderson, executive director of the National Comedy Center, called the decision to end Colbert's show the end of an era. 'Late-night television has historically been one of comedy's most audience-accessible platforms — a place where commentary meets community, night after night,' Gunderson said. 'This isn't just the end of a show. It's the quiet removal of one of the few remaining platforms for daily comedic commentary. Trump celebrates Colbert's demise Trump, who has called in the past for CBS to terminate Colbert's contract, celebrated the show's upcoming demise. 'I absolutely love that Colbert got fired,' the president wrote on Truth Social. 'His talent was even less than his ratings.' Some experts questioned whether CBS could have explored other ways to save money on Colbert. NBC, for example, has cut costs by eliminating the band on Seth Meyers' late-night show and curtailing Jimmy Fallon's 'Tonight' show to four nights a week. Could CBS have saved more money by cutting off the show immediately, instead of letting it run until next May, which sets up an awkward 'lame duck' period? Then again, Colbert will keep working until his contract runs out; CBS would have had to keep paying him anyway. CBS recently cancelled the 'After Midnight' show that ran after Colbert. But the network had signaled earlier this year that it was prepared to continue that show until host Taylor Tomlinson decided that she wanted to leave, noted Bill Carter, author of 'The Late Shift.' 'It is a very sad day for CBS that they are getting out of the late-night race,' Andy Cohen, host of Bravo's 'Watch What Happens Live," told The Associated Press. 'I mean, they are turning off the lights after the news.' Colbert, if he wanted to continue past next May, would likely be able to find a streaming service willing to pay him, Wieser said. But the future of late-night comedy on the entertainment networks is genuinely at risk. Trump, in fact, may outlast his fiercest comic critics. Jon Stewart, once a weeknight fixture, works one night a week at 'The Daily Show' for Paramount's Comedy Central, a network that seldom produces much original programming any more. ABC's Jimmy Kimmel, who was chided on social media by Trump on Friday — 'I hear Jimmy Kimmel is next' — has a contract that also runs out next year. Kimmel, 57, openly wondered in a Variety interview before signing his latest three-year contract extension how long he wanted to do it. He's hosted his show since 2003. 'I have moments where I go, I cannot do this anymore,' Kimmel told Variety in 2022. 'And I have moments where I go, what am I gonna do with my life if I'm not doing this anymore?' It's a very complicated thing ... I'm not going to do this forever.' Colbert, Kimmel and Stewart were all nominated for Emmy awards this week. ___ AP journalist Liam McEwan in Los Angeles contributed to this report. David Bauder writes about the intersection of media and entertainment for the AP. Follow him at and David Bauder, The Associated Press
